- Fertility-sparing treatment in early endometrial cancer: current state and future strategies
-
Obermair A, Baxter E, Brennan DJ, McAlpine JN, Muellerer JJ, Amant F, van Gent MDJM, Coleman RL, Westin SN, Yates MS, Krakstad C, Janda M
- KMID: 2505031
- Obstet Gynecol Sci.
- 2020 Jul;63(4):417-431.
- doi: 10.5468/ogs.19169
Endometrial cancer (EC) is the fifth most common cancer in women worldwide. Global estimates show rising incidence rates in both developed and developing countries. Most women are diagnosed postmenopausal, but... -
- CITED
-
- Close
- SHARE
-
- Close
- PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression
-
Kok PS, Beale P, O'Connell , Grant P, Bonaventura T, Scurry J, Antill Y, Goh J, Sjoquist K, DeFazio A, Mapagu C, Amant F, Friedlander M, on behalf of the PARAGON Investigators
- KMID: 2457159
- J Gynecol Oncol.
- 2019 Sep;30(5):e86.
- doi: 10.3802/jgo.2019.30.e86
OBJECTIVE: A subset of patients with recurrent ovarian cancer (ROC) may benefit from antiestrogen therapy with higher response rates reported in tumors that are strongly estrogen receptor (ER)-positive (ER+). PARAGON... -
- CITED
-
- Close
- SHARE
-
- Close
